This inventor holds 2 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Osaka University, Shionogi Company Limited. Active years: 2020-2024.
Company Filing History:
2 out of 1,040 
2 out of 1,001 
Years Active: 2020-2024
Title: Kanji Hojo: Innovator in Cancer Treatment
Introduction
Kanji Hojo is a notable inventor based in Toyonaka, Japan. He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. With a total of 2 patents, Hojo's work focuses on developing pharmaceutical compositions that target cancer cells effectively.
Latest Patents
Hojo's latest patents include a method of treating cancer with an anti-CCR8 that binds tumor infiltrating cells. This invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8. Another significant patent is a method of treating cancer with an anti-CCR8 having antibody-dependent cell-mediated cytotoxicity (ADCC) activity against cells expressing CCR8. This also offers a pharmaceutical composition for cancer treatment that includes an antibody against CCR8.
Career Highlights
Throughout his career, Kanji Hojo has worked with reputable organizations such as Shionogi & Company Limited and Osaka University. His experience in these institutions has allowed him to advance his research and contribute to the development of innovative cancer therapies.
Collaborations
Hojo has collaborated with notable colleagues, including Tetsuya Yoshida and Yujiro Kidani. These partnerships have played a crucial role in enhancing his research and expanding the impact of his inventions.
Conclusion
Kanji Hojo's contributions to cancer treatment through his patented inventions highlight his dedication to improving healthcare. His innovative methods and collaborations with esteemed organizations and colleagues underscore the importance of research in the fight against cancer.